FP746 : Aqueous biomarker based bespoke therapeutic approach to macular edema in retinal vein occlusions

Dr. Neha Sudhakar Peraka (P18492)

Aim:To analyse outcomes of pharmacotherapy based on biomarker levels for macular edema secondary to retinal vein occlusion.

Methods:Thirty eight eyes were included.Aqueous biomarkers(VEGF,IL6,8)were estimated before and 4 weeks post injection.”3 group” protocol was followed wherein VEGF(high VEGF levels) and Mixed group(high or low VEGF,IL6/8)were given antiVEGF drug while steroid was injected in Interleukin group(high IL6/8).Primary outcome measures were central foveal thickness (CFT), BCVA,and biomarker levels.

Results:While in VEGF group only CVO demonstrated significant improvement in CFT and BCVA(p<0.05),Interleukin group demonstrated the same in both BVO and CVO groups.Non responder eyes demonstrated significant improvement(p=0.05)of both parameters.VEGF and interleukin levels decreased (p<0.05) in eyes with BVO and CVO respectively.

Conclusions:Bespoke therapeutic approach yielded significant improvement in clinical and inflammatory parameters other than simplifying choice of drug